ReviewFrontiers in endocrinology2024
Insulin resistance in NSCLC: unraveling the link between development, diagnosis, and treatment.
Review in Frontiers in endocrinology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 12 citations in OpenAlex.
- Investigating the causal link between metformin and lung cancer risk: a two-sample mendelian randomization analysis.BMC cancer · 2026Article
- Body mass index and fasting insulin predict survival and EGFR-TKI benefit in Stage IV lung adenocarcinoma.Frontiers in oncology · 2026Article
- Dacomitinib in Combination with chemotherapy is effective in lung adenocarcinoma with rareFrontiers in oncology · 2026Article
- Shared genetics of lung cancer and type 2 diabetes: a large-scale genome-wide cross-trait analysis.Translational lung cancer research · 2025Article
- Targeting the molecular crosstalk between diabetes and lung cancer for therapeutic intervention.Discover oncology · 2025Review
- Associations between four insulin resistance (IR) surrogates and the risk of small cell lung cancer (SCLC).Scientific reports · 2025Article
- Prognostic value of the triglyceride-glucose index in advanced gastric cancer: A call for further exploration.World journal of gastroenterology · 2025Article
- The association between triglyceride glucose-body mass index and overall survival in postoperative patient with lung cancer.Frontiers in endocrinology · 2025Article
- Association of triglyceride-glucose index and its combinations with sarcopenia among community-dwelling older adults: based on the Chongqing Aging and Sarcopenia Evaluation (CHASE) cohort.Frontiers in physiology · 2025Article
- PD-1 inhibitor therapy combined with argon-helium cryoablation is effective against non-small cell lung cancer.American journal of translational research · 2025Article
- [Progress in the Study of Mechanisms Clinically Relevant to Insulin Resistance and Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2024Review
- Causal relationship between diabetes mellitus and lung cancer: a two-sample Mendelian randomization and mediation analysis.Frontiers in genetics · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer is responsible for the highest number of cancer-related deaths, with non-small cell lung cancer (NSCLC) being the most prevalent subtype. A critical aspect of managing lung cancer is reducing morbidity and mortality rates among NSCLC patients. Identifying high-risk factors for lung cancer and facilitating early diagnosis are invaluable in achieving this objective. Recent research has highlighted the association between insulin resistance and the development of NSCLC, further emphasizing its significance in the context of lung cancer. It has been discovered that improving insulin resistance can potentially inhibit the progression of lung cancer. Consequently, this paper aims to delve into the occurrence of insulin resistance, the mechanisms underlying its involvement in lung cancer development, as well as its potential value in predicting, assessing, and treating lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.